RGX-104

Cat. No.:	HY-111498A
CAS No.:	610318-54-2
Molecular Formula:	$C_{34}H_{33}ClF_3NO_3$
Molecular Weight:	596.08
Target:	LXR
Pathway:	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (167.76 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.6776 mL	8.3881 mL	16.7763 mL
5 mM	0.3355 mL	1.6776 mL	3.3553 mL
10 mM	0.1678 mL	0.8388 mL	1.6776 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.17 mg/mL (3.64 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.08 mg/mL (3.49 mM); Suspended solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 0.83 mg/mL (1.39 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

RGX-104 is an orally bioavailable and potent liver-X nuclear hormone receptor (LXR) agonist that modulates innate immunity via transcriptional activation of the ApoE gene.

IC_{50} & Target

LXR[1]

In Vivo

Oral administration of RGX-104 (100 mg/kg, daily) to animals bearing palpable tumors significantly suppresses the growth of multiple cancer types. Co-administration of RGX-104 with anti-PD-1 is superior to administration of either RGX-104 or anti-PD-1 alone. Importantly, co-administration of RGX-104 with anti-PD-1 therapy is well tolerated by mice, with no overt signs of toxicity[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD SCID or RAG mice injected with 1×10^6 SKOV3 ovarian cancer cells[1].
Dosage:	100 mg/kg.
Administration:	Oral administration daily for about 60 days.
Result:	Robustly suppressed tumor growth and progression.

CUSTOMER VALIDATION

- Cancer Cell. 2023 May 23;S1535-6108(23)00142-3.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Tavazoie MF, et al. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018 Feb 8;172(4):825-840.e18.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA